Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tregalizumab in active rheumatoid arthritis (NCT01481493)
NCT01481493Phase 2Completed
- Sponsor
- Biotest AG
- Start
- Dec 2010
- Primary completion
- Aug 2013
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of tregalizumab in rheumatoid arthritis (RA), sponsored by Biotest AG. Started Dec 2010; status: completed.
02
Drugs
tregalizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01481493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01481493.